Fer Oviedo

Ciudad de México

[JAMA @JAMA_current]

Among adults with multiorgan metastatic #ColorectalCancer, adding local debulking to chemotherapy did not improve survival and increased serious adverse events.

https://t.co/JwyguzAhmB

[Anirban Maitra @Aiims1742]

Wonderful study in @Cancer_Cell from @skopetz @IamLinghua et al @UTMDAnderson:
Spatial multi-omics landscape of #ColorectalCancer macro- and micrometastases
https://t.co/dSiZ7ZH5oD
Deconstructing the clonal evolution of micromets & TME differences between micro- & macromets.

[Anirban Maitra @Aiims1742]

RAS inhibitors in clinical development
From @papkephd’s website:
https://t.co/lGnbVMfXW7

[Dr Preetam Jain @PreetamJainOnco]

🧬Algorithm of Endometrial Cancer Molecular Classification :

📌 Start with:
✅ MMR Testing
✅ p53 Testing
✅ POLE Mutation Analysis

🔍 Classify into:
🟢 POLE-mutated
🟡 MMR-deficient
🟠 NSMP
🔴 p53-abnormal

⚠️ Some tumors may have more than one molecular subtype — these are called Multiple Classifier Tumors, and the dominant classifier guides prognosis and treatment. (PAGE 2)

🎯 Same Stage ≠ Same Treatment

Modern endometrial cancer management is no longer based on stage alone. Molecular profiling helps personalize adjuvant treatment decisions and identify patients who may benefit from treatment escalation, de-escalation, genetic counseling, or immunotherapy.

#EndometrialCancer #UterineCancer #PrecisionOncology #MolecularOncology #CancerAwareness #MedicalOncology #PersonalizedMedicine #GynecologicOncology #DrPreetamJain

[Karamvir Yadav @K_Yadavir]

Nice review article @JCO_ASCO

Early-onset colorectal cancer is rising—fast. 🚨

And we’re still treating it like traditional CRC.

🧠 Different biology
🧬 More germline mutations
⚠️ More toxicity, not always better outcomes

Here are the clinical takeaways every oncologist should know 👇
#Oncology #ColorectalCancer #MedTwitter @OncoDailyGI @colon @ColonCancerFdn @ASCOPost @ESMO_Open

[ANIMALITOS SANADORES @ANIMALITOSSANA]

El mejor recuerdo de 2020 fue cómo los animales regresaron a las calles mientras los humanos estaban en cuarentena.

[JAMA Surgery @JAMASurgery]

In patients undergoing permanent colostomy for #RectalCancer, use of a funnel-shaped intra-abdominal mesh reduced parastomal hernia incidence and size at 3 years without increased complications compared with no mesh. https://t.co/osOH7q9YSg

[Annals of Surgery @AnnalsofSurgery]

A novel surgical strategy, SURE-LT (SUperior Right Exenteration with Liver Transplantation), combines multivisceral hepatobiliary axis exenteration with liver transplant for patients with locally advanced perihilar cholangiocarcinoma. https://t.co/2yz8J1nbGV

[Yakup Ergün @dr_yakupergun]

Ovarian cancer

https://t.co/FnAWmcsm7f

[Fer Oviedo @Fer25O]

@Gio_Marchegiani @AnnalsofSurgery @jdimick1 @surgery_hps @HpbLounge @hpb_trials @EvidenceMap @T4UGIS @Some4SurgeryIT1 @me4_so @MarcBesselink No

[JAMA @JAMA_current]

🧬 CAR T treatments improve overall survival for patients with large B-cell lymphoma and progression-free survival for patients with multiple myeloma.

💾 Save this Review for your bibliography: https://t.co/ypmwoY6w5w

[BMJ Oncology @BMJOncology]

KRAS, once considered undruggable in cancer, has finally become actionable. Read this new cutting-edge review. https://t.co/UQ9hx9O7b4

[Daniel Castellano @cdanicas]

🎯🎯.- How to apply the current evidence in the treatment of mCSPC!! Excellent review.🙌
https://t.co/OFccsZ439w

👉.- The new molecular precision "triplet intensification" is here.
👉.- A HRR (BRCA2+) alt and pTEN loss population have a poor prognosis.
👉.- We need to better biomarkers profile in this setting
@OncoAlert @APCCC_Lugano @ANZUPtrials @myESMO @GuardConsortium @fedelosco

[Guillaume Laconde @Glaconde34]

A triple-action PROTAC for wild-type p53 cancer therapy: Cell Reports Medicine https://t.co/pfA5mSEiIW

[Yakup Ergün @dr_yakupergun]

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

https://t.co/t2MXPJdaNt

[Fer Oviedo @Fer25O]

@ScooterMagruder They are

[Arndt Vogel @ArndtVogel]

CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
Cancer Treatment Reviews
https://t.co/1eRseKpHeZ
🧐Interesting review on CAR-T cells, the next big wave?
@myESMO @EASLedu @ILCAnews

[Giovanni Marchegiani @Gio_Marchegiani]

Minimally Invasive 🤜 🤛 Open Pancreatoduodenectomy for Resectable Neoplasms @NEJMEvidence 🔴🔴

🏥 RCT 288 pts / 14 centers

🤖 Conversion 8% but ⤵️ time to functional recovery, POPF, SSI

🤝 MI not inferior (in expert hands - in both cases…)

https://t.co/xzPITj7Gc0

[Fer Oviedo @Fer25O]

@ChumelTorres Jajajajaja que es eso

[Fer Oviedo @Fer25O]

@SitoCinema 10